Primary advanced unresectable pancreatic cancer

Area of Science:

• Oncology
• Radiotherapy
• Surgical Oncology

Background:

• Pancreatic cancer has a dismal prognosis with low median and overall survival rates, even with advances in therapy.
• Late diagnosis, aggressive tumor biology, therapy resistance, and limited resection rates contribute to poor outcomes.
• Current treatments often fail to address distant metastases, a primary cause of mortality.

Purpose of the Study:

• To evaluate the efficacy of chemoradiation therapy (CRT) in locally advanced pancreatic cancer.
• To assess the impact of CRT on local tumor control, remission, and survival outcomes.
• To explore strategies for improving treatment outcomes in unresectable pancreatic cancer.

Main Methods:

• Review of various radiotherapy proceedings including intraoperative radiation therapy (IORT) and external CRT.
• Analysis of gemcitabine-associated CRT and neoadjuvant CRT protocols.
• Evaluation of progression samples from patients treated with neoadjuvant or primary radiotherapy.

Main Results:

• Primary CRT, particularly gemcitabine-associated CRT, can achieve local remission in up to 50% of patients.
• Neoadjuvant CRT improves resectability and reduces postoperative lymph node metastasis.
• While CRT enhances local tumor control, its effect on overall survival is often minor, with distant metastases remaining a challenge.
• Combined CRT with continuing chemotherapy is being explored to improve survival.

Conclusions:

• CRT offers significant benefits for local tumor control and remission in advanced pancreatic cancer.
• Improved resectability and reduced local recurrence rates are achievable with neoadjuvant CRT.
• Overcoming distant metastases remains a critical challenge, highlighting the need for combined treatment strategies for advanced pancreatic cancer.